Crossmark

Autoantibody test for type 1 diabetes in children: are there reasons to implement a screening program in the general population? A statement endorsed by the Italian Society for Paediatric Endocrinology and Diabetes (SIEDP-ISPED) and the Italian Society of Paediatrics (SIP)

Crossref DOI link: https://doi.org/10.1186/s13052-023-01438-3

Published Online: 2023-07-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cherubini, Valentino

Chiarelli, Francesco http://orcid.org/0000-0002-3724-1495
License Information

Text and Data Mining valid from 2023-07-19

Version of Record valid from 2023-07-19
More Information

Article History

Received: 22 December 2022

Accepted: 6 March 2023

First Online: 19 July 2023

Declarations

:

: Ethics approval was not required.

: Valentino Cherubini is a Consultant of Astra Zeneca, Dompé, Medtronic and EliLilly; Francesco Chiarelli is Consultant of Merck-Serono Foundation and Provention-Bio.

: Not applicable.

Document is current

Any future updates will be listed below